ArticleFrontiers in oncology2025
Automated predictive framework using AI and deep learning approaches for early detection and classification of liver cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transformer-Driven Explainable Deep Learning with Quantitative Attribution Validation for Liver Tumor Detection.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver cancer, including hepatocellular carcinoma (HCC), is a leading cause of cancer-related deaths globally, emphasizing the need for accurate and early detection methods. Objective: This study introduces LiverCompactNet, an advanced deep learning framework for the early detection and classification of liver cancer. Methods: LiverCompactNet classifies liver images into three categories: benign, malignant, and normal. The dataset comprised 5,000 liver images (1,500 benign, 1,500 malignant, and 2,000 normal), divided into training (3,500), validation (750), and test (750) subsets. Data preprocessing involved normalization using MinMaxScaler, class balancing. Additionally, exploratory Principal Component Analysis (PCA) was performed only on derived tabular features (e.g., intensity histograms, categorical encodings) to visualize variance structure, but PCA was not directly applied to raw imaging data or CNN training inputs. Results: LiverCompactNet demonstrated outstanding performance with an overall accuracy of 99.1%, malignant detection sensitivity of 98.3%, specificity of 99.4%, precision of 97.6%, and an AUC-ROC score of 0.995. Training performance steadily improved, with accuracy rising from 90% in epoch 1 to 99% by epoch 20, and validation accuracy increasing from 88% to 98.5%. Loss analysis revealed effective learning, with training loss approaching zero and validation loss remaining marginally higher. Final evaluations confirmed near-perfect classification metrics: precision at 97.6%, sensitivity at 96.8%, specificity at 98.9%, and an AUC-ROC score of 0.993. Conclusion: LiverCompactNet offers highly accurate, reliable, and early detection capabilities for liver cancer, paving the way for improved medical image analysis and clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.